Antibody Drug Conjugates (ADC) Market Report Scope & Overview:
The Antibody Drug Conjugates [ADC] Market was valued at USD 12.29 billion in 2024 and is expected to reach USD 29.10 billion by 2032, growing at a CAGR of 12.29% from 2025-2032.
Get More Information on Antibody Drug Conjugates (ADC) Market - Request Sample Report
The antibody drug conjugates market is growing swiftly as a result of the rising need for targeted treatments for cancer. ADCs, merging the specificity of monoclonal antibodies with the strength of cytotoxic drugs, are increasingly popular for their capability to provide precisely targeted therapies to cancer cells while reducing harm to healthy tissues. The market is experiencing progress in ADC technology, which is improving drug effectiveness and minimizing side effects. Recent advancements in ADCs, including the arrival of next-generation conjugates and innovative targeting methods, are anticipated to drive further market growth.
Innovations in linker chemistry, cytotoxic compounds, and targeting strategies are propelling market advancements. Firms such as Gilead Sciences and Bristol Myers Squibb are actively putting resources into ADC development, as clinical trials and regulatory approvals speed up. In January 2024, Johnson & Johnson purchased Ambrx Biopharma to utilize its unique ADC technology, concentrating on treatments for prostate cancer. In early 2024, Celltrion and WuXi XDC formed a partnership to enhance ADC development and production.
Market Size and Forecast:
-
Market Size in 2024 USD 11.53 Billion
-
Market Size by 2032 USD 29.10 Billion
-
CAGR of 12.29% From 2025 to 2032
-
Base Year 2024
-
Forecast Period 2025-2032
-
Historical Data 2021-2023
Antibody Drug Conjugates [ADC] Market Trends:
-
Rising global cancer incidence is driving demand for targeted therapies like antibody-drug conjugates (ADCs).
-
ADCs offer precise delivery of cytotoxic drugs, reducing damage to healthy cells compared to traditional chemotherapy.
-
Increasing approvals of ADCs for breast, lung, and hematological cancers highlight growing clinical adoption.
-
Continuous advancements in linker chemistry, payloads, and targeting mechanisms are enhancing ADC efficacy and safety.
-
Collaborations and investments in ADC development and manufacturing are accelerating innovation and the number of ADCs entering clinical trials.
Antibody Drug Conjugates [ADC] Market Growth Drivers:
-
The global rise in cancer cases is one of the primary drivers propelling the Antibody Drug Conjugates (ADC) market.
One of the major factors propelling the Antibody Drug Conjugates (ADC) market is the increasing incidence of cancer worldwide. According to the World Health Organization (WHO) In 2022, it is estimated that 20 million new cases of cancer and 9.7 million deaths occurred. The estimated number of cancer survivors in 5 years post-diagnosis was 53.5 million. Approximately 1 in 5 persons develop cancer in their lifetime, and approximately 1 in 9 men and 1 in 12 women die from the disease. This rising cancer burden increases the need for more effective treatments. These antibody-drug conjugates (ADCs) deliver cytotoxic drugs directly to the cancer cell, in contrast to traditional chemotherapy, which can also affect healthy cells. Because of their targeting ability of specific tumor cells to occupy and decrease adverse effects, ADC may be an interesting tool in cancer therapy. Consequently, ADCs are increasingly attracting oncologists, especially for breast, lung, and hematological cancers.
The growing significance of ADCs is underscored by recent advances in this space, for instance, the approval of Trodelvy (sacituzumab govitecan) for metastatic triple-negative breast cancer (mTNBC). Moreover, the increasing burden of cancers in emerging markets driven by changing lifestyles and aging demographics also bolsters the demand for innovative therapies such as ADCs.
-
Continuous advancements in ADC technology are significantly enhancing the efficacy and safety profiles of these therapies, driving market growth.
Novel ADC technologies continue to progress and are improving the effectiveness and safety of these therapies meaningfully contributing to the growth of the market. Advances in linker chemistry, payloads, and targeting mechanisms are enhancing ADCs' capabilities to deliver cytotoxic agents directly to cancer cells while reducing systemic negativity. Novel mechanisms of action for next-generation ADCs garnering significant investment from pharma.
For instance, in January 2024, Celltrion collaborated with WuXi XDC to improve ADC development and manufacturing. Now, Peking University, Han's research team, and Huadong Medicine have the support of Fusion as a service intelligence network in establishing Huadong Medicine to yield better ADC technology by environmentally improving production processes and drug efficacy. For instance, the first approval of ADC was Kadcya (ado-trastuzumab emtansine) and Enhertu (fam-trastuzumab deruxtecan-nxki) further consolidated the capability of ADC in a new era of cancer which was used as a frontline treatment in cancer as well. These advancements in ADC technology, along with an increasing number of ADCs entering clinical trials, are projected to further propel MDC growth.
Antibody Drug Conjugates [ADC] Market Restraints:
-
One of the key restraints for the Antibody Drug Conjugates (ADC) market is the high production costs associated with the development and manufacturing of these complex therapies.
ADCs are created by conjugating cytotoxic drugs to monoclonal antibodies using technologies that are cutting-edge and combine unique types of manufacturing processes. The complex production processes of the antibodies and cytotoxic agents and the conjugation process, in general, are expensive. The high costs associated with these therapies can result in expensive pricing for end-users, rendering ADCs less accessible in specific geographical regions or markets, and potentially hindering their adoption on a larger scale despite their enormous therapeutic potential. Moreover, the demanding regulatory scrutiny and quality control requirements elevate costs, which could dissuade small market participants or hinder investments in ADC R&D.
Antibody Drug Conjugates [ADC] Market Segment Analysis:
By Application
In 2024, the breast cancer segment dominated the market, contributing 48% of the market share to reasons such as a rising number of cases, promising pipeline products, and widespread usage of Kadcyla. Trodelvy, Enhertu, and Kadcyla are the drugs approved for treating breast cancer. The addition of Kadcyla for early breast cancer patients and the recent approvals of Enhertu and Trodelvy should provide a fillip to the segment. The
Blood cancer is exhibited to witness the fastest growth. Blood cancer is the 5th most common kind of cancer and the second leading cause of cancer deaths in the world. According to the National Foundation for Cancer Research, about 186,400 new cases of leukemia, lymphoma, and myeloma were diagnosed in the U.S. in 2022. Moreover, the approval of multiple products during the forecast period is expected to propel market growth.
By Target
In 2024, the HER2 segment, or human epidermal growth factor receptor 2, dominated the market with a significant share. HER2 is a crucial target. It's critical in the treatment of breast cancer, where overexpression is common. ADCs target HER2 with potent drugs that can be delivered directly to cancer cells, sparing healthy cells and enhancing treatment activity. Because of those things, the uptake is significant and that's contributed to propelling this segment’s leadership in the industry.
Over the forecast period, CD22 is one of the fastest-developing target segments. The field here is characterized by its broad application in cancer treatment, such as in leukemias, making it the fastest-growing niche in the area. CD22 antigen leukemia-associated diseases are increasingly indicating the growing demand for effective and low-side effect treatments CD22 targeted treatments are rapidly being regulated due to their clinical promise and are increasingly becoming a preferred treatment regimen among physicians and patients alike.
By Product
Kadcyla dominated the ADC market in 2024, propelled by an increasing incidence of breast cancer and more approvals of ADCs specifically for breast cancer. In January 2022, Kadcyla received a big boost with a green signal for use in China by F. Hoffmann-La Roche Ltd., a new market with high growth potential. The broad uptake of Kadcyla also highlights a growing market for targeted cancer immunotherapies, marking the largest revenue-generating ADC addressable market.
Enhertu has become the fastest growing segment of the ADC market. The collaboration with Daiichi Sankyo and AstraZeneca has also driven Enhertu's rapid rise, especially after it was approved for HER2-low breast cancer in August 2022, a watershed moment in oncology treatment. Additionally, despite competitive activity from other brands that have entered the market, including second-line HER2-positive breast cancer indications for Enhertu since May 2022, this product has consistently claimed an early lead for share of new patients and signaled rapid adoption in the market. The continue expansion of its indications anticipated to bring continued growth in the forthcoming years.
Need any customization research on Antibody Drug Conjugates (ADC) Market - Enquiry Now
Antibody Drug Conjugates [ADC] Market Regional Analysis:
North America Antibody Drug Conjugates [ADC] Market Insights
North America dominated the Antibody Drug Conjugates (ADC) market with a 51% market share, owing to its sophisticated healthcare system, robust biopharmaceutical environment, and substantial funding in research and development. The area experiences a significant rate of cancer, increasing the need for advanced therapies such as ADCs, which provide targeted care with few side effects. The existence of key firms like Seagen, Pfizer, and ImmunoGen promotes innovation and speeds up ADC advancement. Moreover, the U.S. Food and Drug Administration (FDA) offers accelerated regulatory routes, allowing quicker approvals and market entry. North America gains significant financial support for cancer research and strategic partnerships among biopharma companies to improve ADC development. The region stays at the leading edge of the ADC market, significantly boosting its growth, due to its well-developed healthcare system and strong awareness of advanced treatments.
Asia Pacific Antibody Drug Conjugates [ADC] Market Insights
Asia Pacific region is the fastest growing region in the Antibody Drug Conjugates (ADC) market with the fastest growing CAGR of 15.73%, due to the increasing prevalence of cancer, rise in healthcare expenditure, and growing biopharmaceutical ecosystem in this region. With a vast and aging population, the region has a high cancer burden, leading to significant unmet demand for targeted therapies such as ADCs. China, India, South Korea, and a handful of others are evolving with major changes to healthcare infrastructure and biotechnology, encouraging breakthroughs and access to advanced treatment solutions. Local biopharma companies such as Shanghai Miracogen and Innovent Biologics participate in market expansion via clinical trials and affordable ADCs. Governments are also speeding up regulatory approvals, and awareness and access to cancer diagnostics and therapies are improving. Together, they propel the accelerated market growth.
Europe Antibody Drug Conjugates [ADC] Market Insights
Europe’s ADC market is expanding due to increasing cancer prevalence, advanced healthcare infrastructure, and growing adoption of targeted therapies. Rising approvals of novel ADCs for breast, lung, and hematological cancers, coupled with strong R&D investments and collaborations among pharmaceutical companies, are driving market growth. The focus on precision medicine and improved treatment efficacy further enhances regional adoption.
Latin America (LATAM) and Middle East & Africa (MEA) Antibody Drug Conjugates [ADC] Market Insights
The LATAM and MEA ADC markets are growing with rising cancer incidence, improving healthcare infrastructure, and increased awareness of targeted therapies. Emerging markets are witnessing expanding clinical trials and collaborations, supporting ADC development. Adoption of innovative ADC technologies and focus on patient-centric therapies are fueling regional market growth despite budgetary and accessibility challenges.
Antibody Drug Conjugates [ADC] Market Key Players:
-
Genentech (Herceptin, Kadcyla)
-
Seagen Inc. (Adcetris, Tivdak)
-
AstraZeneca (Enhertu, Lumoxiti)
-
Daiichi Sankyo (Enhertu, DS-8201)
-
Pfizer (Besponsa, Mylotarg)
-
ImmunoGen (Mirvetuximab soravtansine, Epotuzumab)
-
Bristol Myers Squibb (Empliciti, Opdivo + Yervoy)
-
Amgen (Blincyto, Omecamtiv mecarbil)
-
ADC Therapeutics (Lonca, Zynlonta)
-
MacroGenics (Margetuximab, Enoblituzumab)
-
Bayer (BAY 94-9343, Fresenius Kabi ADC)
-
Zymeworks (Zymeworks 857, ZW49)
-
Gilead Sciences (Yescarta, Kymriah)
-
Mersana Therapeutics (XMT-1536, XMT-1592)
-
Boehringer Ingelheim (M-Tor, BI 836880)
-
Sanofi (SAR408701, SAR566658)
-
Eli Lilly (Mirvetuximab soravtansine, Tiragolumab)
-
Janssen Biotech (Darzalex, Balversa)
-
Roche (Tecentriq, Gazyva)
-
Curis Inc. (CA-170, CI-8993)
Competitive Landscape for Antibody Drug Conjugates [ADC] Market:
Celltrion, Inc. is a leading biopharmaceutical company specializing in the development and manufacturing of antibody-drug conjugates (ADCs). Leveraging advanced biotechnology and collaborative partnerships, Celltrion focuses on creating targeted cancer therapies that enhance efficacy while minimizing side effects. Its innovations in ADC technology support clinical advancements and broaden treatment options for oncology patients worldwide.
-
In January 2024, Celltrion, Inc. and WuXi XDC signed a Memorandum of Understanding (MOU) to offer integrated services for the development and manufacturing of antibody-drug conjugates (ADCs). This collaboration aims to enhance the capabilities of both companies in delivering ADC solutions.
| Report Attributes | Details |
|---|---|
| Market Size in 2024 | USD 11.53 Billion |
| Market Size by 2032 | USD 29.10 Billion |
| CAGR | CAGR of 12.29% From 2025 to 2032 |
| Base Year | 2024 |
| Forecast Period | 2025-2032 |
| Historical Data | 2021-2023 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Application (Blood Cancer, Breast Cancer, Urothelial Cancer & Bladder Cancer, Other Cancer) • By Product (Kadcyla, Enhertu, Adcetris, Padcev, Trodelvy, Polivy, Others) • By Target (HER2, CD22, CD30, Others) • By Technology (Technology Type, Linker Technology Type, Payload Technology) |
| Regional Analysis/Coverage | North America (US, Canada), Europe (Germany, UK, France, Italy, Spain, Russia, Poland, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN Countries, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Mexico, Colombia, Rest of Latin America). |
| Company Profiles | Genentech, Seagen Inc., AstraZeneca, Daiichi Sankyo, Pfizer, ImmunoGen, Bristol Myers Squibb, Amgen, ADC Therapeutics, MacroGenics, Bayer, Zymeworks, Gilead Sciences, Mersana Therapeutics, Boehringer Ingelheim, Sanofi, Eli Lilly, Janssen Biotech, Roche, Curis Inc., and other players. |
| Key Drivers | •The global rise in cancer cases is one of the primary drivers propelling the Antibody Drug Conjugates (ADC) market. •Continuous advancements in ADC technology are significantly enhancing the efficacy and safety profiles of these therapies, driving market growth. |
Table Of Contents
1. Introduction
1.1 Market Definition & Scope
1.2 Research Assumptions & Abbreviations
1.3 Research Methodology
2. Executive Summary
2.1 Market Snapshot
2.2 Market Absolute $ Opportunity Assessment & Y-o-Y Analysis, 2021–2032
2.3 Market Size & Forecast, By Segmentation, 2021–2032
2.3.1 Market Size By Application
2.3.2 Market Size By Product
2.3.3 Market Size By Target
2.3.4 Market Size By Technology
2.4 Market Share & Bps Analysis By Region, 2024
2.5 Industry Growth Scenarios – Conservative, Likely & Optimistic
2.6 Industry CxO’s Perspective
3. Market Overview
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Key Market Trends
3.2 Industry PESTLE Analysis
3.3 Key Industry Forces (Porter’s) Impacting Market Growth
3.4 Industry Supply Chain Analysis
3.4.1 Raw Material Suppliers
3.4.2 Manufacturers
3.4.3 Distributors/Suppliers
3.4.4 Customers/End-Users
3.5 Industry Life Cycle Assessment
3.6 Parent Market Overview
3.7 Market Risk Assessment
4. Statistical Insights & Trends Reporting
4.1 Clinical Performance & Efficacy Metrics
4.1.1 Average overall response rate (ORR %) of ADC therapies in clinical trials
4.1.2 Average progression-free survival (PFS, months) achieved by approved ADCs
4.1.3 Average reduction (%) in off-target toxicity compared to conventional chemotherapy
4.2 Adoption & Treatment Trends
4.2.1 Share of ADC adoption by cancer type (breast, hematologic, lung, others) (%)
4.2.2 Year-on-year growth (%) in ADC prescriptions globally
4.2.3 Share of ADCs used as monotherapy vs combination therapy (%)
4.3 R&D & Pipeline Development Metrics
4.3.1 Number of ADCs in preclinical, Phase I, Phase II, and Phase III trials
4.3.2 Share of ADC pipeline by target antigen type (HER2, CD30, TROP2, others) (%)
4.3.3 Average clinical trial success rate (%) for ADCs compared to other oncology drugs
4.4 Cost & Accessibility Benchmarks
4.4.1 Average treatment cost (USD) per patient for ADC therapies
4.4.2 Share of ADC therapies covered under reimbursement programs (by region) (%)
4.4.3 Average reduction (%) in hospital stays or supportive care costs with ADC adoption
5. Antibody Drug Conjugates [ADC] Market Segmental Analysis & Forecast, By Application, 2021 – 2032, Value (USD Billion)
5.1 Introduction
5.2 Blood Cancer
5.2.1 Key Trends
5.2.2 Market Size & Forecast, 2021 – 2032
5.3 Breast Cancer
5.4 Urothelial Cancer & Bladder Cancer
5.5 Other Cancer
6. Antibody Drug Conjugates [ADC] Market Segmental Analysis & Forecast, By Product, 2021 – 2032, Value (USD Billion)
6.1 Introduction
6.2 Kadcyla
6.2.1 Key Trends
6.2.2 Market Size & Forecast, 2021 – 2032
6.3 Enhertu
6.4 Adcetris
6.5 Trodelvy
6.6 Polivy
6.7 Others
7. Antibody Drug Conjugates [ADC] Market Segmental Analysis & Forecast, By Target, 2021 – 2032, Value (USD Billion)
7.1 Introduction
7.2 HER2
7.2.1 Key Trends
7.2.2 Market Size & Forecast, 2021 – 2032
7.3 CD22
7.3 CD30
7.3 Others
8. Antibody Drug Conjugates [ADC] Market Segmental Analysis & Forecast, By Technology, 2021 – 2032, Value (USD Billion)
8.1 Introduction
8.2 Technology Type
8.2.1 Key Trends
8.2.2 Market Size & Forecast, 2021 – 2032
8.3 Linker Technology Type
8.4 Payload Technology
9. Antibody Drug Conjugates [ADC] Market Segmental Analysis & Forecast By Region, 2021 – 2025, Value (USD Billion)
9.1 Introduction
9.2 North America
9.2.1 Key Trends
9.2.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.2.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.2.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.2.5 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.2.6 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Country, 2021 – 2032
9.2.6.1 USA
9.2.6.1.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.2.6.1.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.2.6.1.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.2.6.1.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.2.6.2 Canada
9.2.6.2.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.2.6.2.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.2.6.2.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.2.6.2.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.3 Europe
9.3.1 Key Trends
9.3.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.3.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.3.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.3.5 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.3.6 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Country, 2021 – 2032
9.3.6.1 Germany
9.3.6.1.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.3.6.1.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.3.6.1.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.3.6.1.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.3.6.2 UK
9.3.6.2.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.3.6.2.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.3.6.2.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.3.6.2.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.3.6.3 France
9.3.6.3.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.3.6.3.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.3.6.3.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.3.6.3.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.3.6.4 Italy
9.3.6.4.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.3.6.4.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.3.6.4.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.3.6.4.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.3.6.5 Spain
9.3.6.5.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.3.6.5.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.3.6.5.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.3.6.5.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.3.6.6 Russia
9.3.6.6.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.3.6.6.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.3.6.6.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.3.6.6.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.3.6.7 Poland
9.3.6.7.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.3.6.7.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.3.6.7.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.3.6.7.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.3.6.8 Rest of Europe
9.3.6.8.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.3.6.8.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.3.6.8.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.3.6.8.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.4 Asia-Pacific
9.4.1 Key Trends
9.4.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.4.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.4.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.4.5 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.4.6 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Country, 2021 – 2032
9.4.6.1 China
9.4.6.1.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.4.6.1.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.4.6.1.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.4.6.1.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.4.6.2 India
9.4.6.2.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.4.6.2.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.4.6.2.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.4.6.2.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.4.6.3 Japan
9.4.6.3.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.4.6.3.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.4.6.3.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.4.6.3.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.4.6.4 South Korea
9.4.6.4.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.4.6.4.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.4.6.4.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.4.6.4.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.4.6.5 Australia
9.4.6.5.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.4.6.5.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.4.6.5.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.4.6.5.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.4.6.6 ASEAN Countries
9.4.6.6.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.4.6.6.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.4.6.6.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.4.6.6.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.4.6.7 Rest of Asia-Pacific
9.4.6.7.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.4.6.7.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.4.6.7.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.4.6.7.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.5 Latin America
9.5.1 Key Trends
9.5.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.5.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.5.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.5.5 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.5.6 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Country, 2021 – 2032
9.5.6.1 Brazil
9.5.6.1.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.5.6.1.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.5.6.1.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.5.6.1.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.5.6.2 Argentina
9.5.6.2.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.5.6.2.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.5.6.2.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.5.6.2.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.5.6.3 Mexico
9.5.6.3.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.5.6.3.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.5.6.3.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.5.6.3.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.5.6.4 Colombia
9.5.6.4.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.5.6.4.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.5.6.4.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.5.6.4.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.5.6.5 Rest of Latin America
9.5.6.5.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.5.6.5.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.5.6.5.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.5.6.5.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.6 Middle East & Africa
9.6.1 Key Trends
9.6.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.6.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.6.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.6.5 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.6.6 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Country, 2021 – 2032
9.6.6.1 UAE
9.6.6.1.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.6.6.1.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.6.6.1.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.6.6.1.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.6.6.2 Saudi Arabia
9.6.6.2.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.6.6.2.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.6.6.2.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.6.6.2.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.6.6.3 Qatar
9.6.6.3.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.6.6.3.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.6.6.3.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.6.6.3.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.6.6.4 Egypt
9.6.6.4.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.6.6.4.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.6.6.4.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.6.6.4.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.6.6.5 South Africa
9.6.6.5.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.6.6.5.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.6.6.5.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.6.6.5.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
9.6.6.6 Rest of Middle East & Africa
9.6.6.6.1 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Application, 2021 – 2032
9.6.6.6.2 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Product, 2021 – 2032
9.6.6.6.3 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Target, 2021 – 2032
9.6.6.6.4 Antibody Drug Conjugates [ADC] Market Size & Forecast, By Technology, 2021 – 2032
10. Competitive Landscape
10.1 Key Players' Positioning
10.2 Competitive Developments
10.2.1 Key Strategies Adopted (%), By Key Players, 2024
10.2.2 Year-Wise Strategies & Development, 2021 – 2025
10.2.3 Number Of Strategies Adopted By Key Players, 2024
10.3 Market Share Analysis, 2024
10.4 Product/Service & Application Benchmarking
10.4.1 Product/Service Specifications & Features By Key Players
10.4.2 Product/Service Heatmap By Key Players
10.4.3 Application Heatmap By Key Players
10.5 Industry Start-Up & Innovation Landscape
10.6 Key Company Profiles
10.6.1 Genentech.
10.6.1.1 Company Overview & Snapshot
10.6.1.2 Product/Service Portfolio
10.6.1.3 Key Company Financials
10.6.1.4 SWOT Analysis
10.6.2 Seagen Inc.
10.6.3 AstraZeneca
10.6.4 Daiichi Sankyo
10.6.5 Pfizer
10.6.6 ImmunoGen
10.6.7 Bristol Myers Squibb
10.6.8 Amgen
10.6.9 ADC Therapeutics
10.6.10 MacroGenics
10.6.11 Bayer
10.6.12 Zymeworks
10.6.13 Gilead Sciences
10.6.14 Mersana Therapeutics
10.6.15 Boehringer Ingelheim
10.6.16 Sanofi
10.6.17 Eli Lilly
10.6.18 Janssen Biotech
10.6.19 Roche
10.6.20 Curis Inc.
11. Analyst Recommendations
11.1 SNS Insider Opportunity Map
11.2 Industry Low-Hanging Fruit Assessment
11.3 Market Entry & Growth Strategy
11.4 Analyst Viewpoint & Suggestions On Market Growth
12. Assumptions
13. Disclaimer
14. Appendix
14.1 List Of Tables
14.2 List Of Figures
Key Segments:
By Application
-
-
Blood Cancer
-
Leukemia
-
-
-
-
-
Lymphoma
-
-
-
-
-
Multiple Myeloma
-
-
-
-
Breast Cancer
-
-
-
Urothelial Cancer & Bladder Cancer
-
-
-
Other Cancer
-
By Product
-
-
Kadcyla
-
-
-
Enhertu
-
-
-
Adcetris
-
-
-
Padcev
-
-
-
Trodelvy
-
-
-
Polivy
-
-
-
Others
-
By Target
-
-
HER2
-
-
-
CD22
-
-
-
CD30
-
-
-
Others
-
By Technology
-
-
Technology Type
-
Cleavable Linker
-
-
-
-
-
Non-cleavable Linker
-
-
-
-
-
Linkerless
-
-
-
-
Linker Technology Type
-
VC
-
-
-
-
-
Sulfo-SPDB
-
-
-
-
-
VA
-
-
-
-
-
Hydrazone
-
-
-
-
-
Others
-
-
-
-
Payload Technology
-
MMAE
-
-
-
-
-
MMAF
-
-
-
-
-
DM4
-
-
-
-
-
Camptothecin
-
-
-
-
-
Others
-
-
Request for Segment Customization as per your Business Requirement: Segment Customization Request
REGIONAL COVERAGE:
North America
-
US
-
Canada
-
Mexico
Europe
-
Eastern Europe
-
Poland
-
Romania
-
Hungary
-
Turkey
-
Rest of Eastern Europe
-
-
Western Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Netherlands
-
Switzerland
-
Austria
-
Rest of Western Europe
-
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Vietnam
-
Singapore
-
Australia
-
Rest of Asia Pacific
Middle East & Africa
-
Middle East
-
UAE
-
Egypt
-
Saudi Arabia
-
Qatar
-
Rest of the Middle East
-
-
Africa
-
Nigeria
-
South Africa
-
Rest of Africa
-
Latin America
-
Brazil
-
Argentina
-
Colombia
-
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization to meet the company’s specific needs. The following customization options are available for the report:
-
Product Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Product Matrix which gives a detailed comparison of the product portfolio of each company
-
Geographic Analysis
-
Additional countries in any of the regions
-
Company Information
-
Detailed analysis and profiling of additional market players (Up to five)
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
